Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide.

Jean Charles Rousseau, Linda J. Sandell, Pierre D. Delmas, Patrick Garnero

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Type II collagen, the most abundant protein of cartilage matrix, is synthesized as a procollagen molecule including the N-(PIINP) and C-(PIICP) propeptides at each end. Type II procollagen is produced in two forms as the result of alternative RNA splicing. One form (IIA) includes and the other form (IIB) excludes a 69-amino acid cysteine-rich globular domain encoded by exon 2 in PIINP. During the process of synthesis, these N-propeptides are removed by specific proteases and released in the circulation, and their levels are believed to reflect type II collagen synthesis. In this chapter we describe the development of a specific enzyme-linked immunosorbent assay (ELISA) for the measurement of the IIA form of PIINP (PIIANP) in serum based on a polyclonal antibody raised against recombinant human exon 2 fusion protein of type II procollagen. We show that this ELISA is highly specific for circulating PIIANP and has adequate technical precision. In patients with knee osteoarthritis and rheumatoid arthritis, serum PIIANP was decreased by 53% (p < 0.0001) and 35% (p < 0.001), respectively, suggesting that type IIA collagen synthesis is altered in these arthritic diseases. The measurement of serum PIIANP may be useful for the clinical investigation of patients with joint diseases.

Original languageEnglish
Pages (from-to)25-37
Number of pages13
JournalMethods in Molecular Medicine
StatePublished - 2004


Dive into the research topics of 'Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide.'. Together they form a unique fingerprint.

Cite this